Summary

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

• Eptinezumab-jjmr (Vyepti) is indicated for the preventive treatment of migraine in adults and has demonstrated a favorable safety profile across various studies, with no significant difference in treatment-related adverse events compared to placebo.
• The review process involved 15 systematic reviews/meta-analyses that provided comprehensive information about Vyepti's comparison to other drugs regarding safety and effectiveness for preventing migraines in adults.
• Compared to other monoclonal antibodies targeting the calcitonin gene-related peptide pathway and gepants, eptinezumab shows similar levels of safety. However, it has a slightly higher occurrence of infusion-site adverse events than placebos.
• In terms of efficacy, eptinezumab consistently reduces monthly migraine days according to multiple systematic reviews and meta-analyses. It also stands out due to its rapid onset, which starts reducing migraine rates from day one after dosing.
• When comparing eptinezumab's effectiveness against other CGRP-targeting therapies, results vary; some analyses suggest it is among the most effective treatments, while others favor different options.
• Network meta-analyses highlight eptinezumab’s substantial effect on decreasing monthly headache days and achieving high responder rates, especially at its 300mg dosage level.
• A study addressing cost-effectiveness found that although eptinezumab generated the most quality-adjusted life years (QALYs), topiramate was identified as more cost-effective by comparison within the UK context.
• Subpopulation efficacy analysis reveals promising outcomes with the use of eptinezumab-jjmr, particularly at a 300mg dose, amongst patients who had a previous history of treatment failure.